

C-Reactive Protein in Young, Apparently Healthy Men: Associations With Serum Leptin, QTc Interval, and High-Density Lipoprotein-Cholesterol

Tsutomu Kazumi, Akira Kawaguchi, Tsutomu Hirano, and Gen Yoshino

To determine which anthropometric, biochemical, and cardiovascular variables are associated with serum levels of C-reactive protein (CRP) in young, apparently healthy men, a cross-sectional study of 179 male college students aged 18 to 22 years was performed. Multiple regression analysis was used to derive models for serum CRP concentrations in terms of the other variables measured. Although CRP was positively correlated with body mass index (BMI), percent fat mass, and serum leptin, correlations with BMI ($r = 0.15$, $P = .05$) and percent body fat ($r = 0.16$, $P = .003$) were not as strong as the correlation with leptin ($r = 0.28$, $P = .0002$). CRP was also associated with resting heart rate ($r = 0.14$, $P = .05$), heart-rate corrected QT (QTc) interval ($r = 0.22$, $P = .003$) and several components of the insulin resistance (IR) syndrome. CRP showed a strong and negative association with high-density lipoprotein (HDL)-cholesterol ($r = -0.26$, $P = .0005$) and a marginal and positive association with triglyceride ($r = 0.14$, $P = .05$). Although CRP was associated with fasting insulin ($r = 0.15$, $P = .04$), it was not related to serum adiponectin or IR index estimated using homeostasis model assessment (HOMA). Multiple regression analysis indicated that serum CRP was positively related to serum leptin ($P = .003$) and QTc interval ($P = .01$), and negatively correlated with HDL-cholesterol ($P = .01$, $R^2 = 0.15$). In young, apparently healthy men, serum leptin but not BMI was independently associated with serum CRP, suggesting that amount of body fat may be the most significant predictor of CRP. Although low-grade inflammation was associated with long QTc interval and low HDL-cholesterol, the mechanism underlying these associations is an important question to be addressed.

© 2003 Elsevier Inc. All rights reserved.

OBESITY is a pan-endemic health problem in both developed and developing countries. It predisposes to a host of complications including such major sources of morbidity and mortality as coronary artery disease, type 2 diabetes, and cancer. The pathogenesis of obesity-related complications remains the subject of much research. An interesting line of research is the role of obesity in the production of cytokines. Adipose tissue is now acknowledged to be a source of cytokines such as tumor necrosis factor- α and interleukin-6.^{1,2} Interleukin-6 stimulates hepatocytes to produce a variety of acute phase reactants.³⁻⁵ Several studies have found that body mass index (BMI) is strongly associated with C-reactive protein (CRP), one such acute-phase reactant, suggesting that obesity may be a state of low-grade inflammation.⁶⁻¹³

Recently, CRP has been revealed to show a strong independent association with risk of coronary heart disease and other atherothrombotic events.¹⁴⁻¹⁷ CRP levels have also been found to correlate with some features of insulin resistance (IR) syndrome.^{13,17-21} Therefore, the aim of the present study was to examine whether CRP levels are driven by parameters related to the IR syndrome, including serum leptin and adiponectin, both of which have been reported to be associated with insulin resistance.^{22,23} The analyses were done in apparently healthy men aged 18 to 22 years.²⁴

MATERIALS AND METHODS

One hundred ninety-eight men entered Kobe University of Merchantile Marine, Kobe, Japan, in 1997. They all were Japanese and were aged 18 to 22 years. One hundred seventy-nine serum samples were available for CRP measurements and there were no significant differences between the 179 men and the remaining 11 men whose sera were not available for CRP determinations regarding the physical, biochemical, and cardiovascular variables described in Table 1 (data not shown).

Body weights and percent body fat were measured after the subjects fasted overnight and voided. This was done using an impedance fat meter (TBF-202, Tanita Corp, Tokyo, Japan). TBF-202 employs 2-foot pad electrodes with a corresponding digital scale, as previously reported.²⁵

Blood pressure was measured with a standard mercury sphygmoma-

nometer after the subjects had rested at least 10 minutes. Systolic blood pressure was recorded at the appearance of sounds and diastolic blood pressure was recorded at the disappearance of sounds (V-phase Korotkov). The measurements were repeated after 2 to 3 minutes and the average of the measurements were used in analysis.

Alcohol consumption and smoking habits were determined by an interview at the time of each participant's physical examination. Data with respect to diet and exercise were not available. Nobody received any medications.

Twelve-lead electrocardiograms were recorded at a 25 mm/s paper speed and at 10 mm/mV gain by means of an automated electrocardiogram (FCP-4266, Fukuda Denshi, Tokyo, Japan). A differential threshold technique²⁶ was used for determinations of QT interval and then QTc was calculated using Bazett's formula: $QTc = QT / \sqrt{RR}$.

The computer program uses successive R-R intervals between all ventricular muscle depolarization (QRS complexes) to calculate the mean heart rate within the recorded period of 10 seconds. Sinus rhythm was present in all participants and in none of the electrocardiograms were repolarization disturbances detectable.

Venous blood was sampled after an overnight fast and centrifuged at 3,000 rpm for 30 minutes at 4°C. Plasma glucose was measured by the glucose oxidase method. Insulin and leptin were assayed using commercially available kits (Pharmacia, Tokyo, Japan, and Linco Research, St Charles, MO, respectively). Cholesterol, triglyceride, HDL-cholesterol, and apolipoproteins were measured as previously reported.²⁵

From the Department of Food Science and Nutrition, School of Human Environmental Science, Mukogawa Women's University, Health Science Center, Nishonomiya, Japan; Kobe University of Merchantile Marine, First Department of Internal Medicine, Kobe, Japan; and the Showa University School of Medicine, Department of Laboratory Medicine, Toho University School of Medicine, Tokyo, Japan.

Submitted August 31, 2002; accepted April 21, 2003.

Address reprint requests to Tsutomu Kazumi, MD, PhD, Department of Food Science and Nutrition, School of Human Environmental Science, Mukogawa Women's University, 6-46 Ikebiraki-cho, Nishonomiya, Hyogo 663-8558, Japan.

© 2003 Elsevier Inc. All rights reserved.

0026-0495/03/5209-0004\$30.00/0

doi:10.1016/S0026-0495(03)00184-7

Table 1. Descriptive Data and Spearman's Correlation Coefficients (*r*) for CRP With Components of the IR Syndrome in 179 Apparently Healthy Men Aged 18 to 22 Years

| | Mean | SD | Median | <i>r</i> |
|---------------------------|------|------|--------|----------|
| BMI (kg/m ²) | 21.8 | 3.7 | 21.1 | 0.14* |
| Percentage body fat (%) | 18.6 | 6.0 | 17.4 | 0.16* |
| Serum leptin (ng/mL) | 2.3 | 2.9 | 1.4 | 0.28† |
| Systolic BP (mm Hg) | 121 | 13 | 122 | 0.10 |
| Diastolic BP (mm Hg) | 72 | 8 | 71 | 0.04 |
| Resting heart rate (bpm) | 65 | 10 | 65 | 0.14* |
| QTc duration (ms) | 387 | 22 | 385 | 0.22† |
| Total cholesterol (mg/dL) | 177 | 29 | 170 | -0.02 |
| LDL-cholesterol (mg/dL) | 107 | 27 | 102 | 0.02 |
| HDL-cholesterol (mg/dL) | 57 | 10 | 56 | -0.26‡ |
| Triglyceride (mg/dL) | 63 | 33 | 57 | 0.14* |
| Apolipoprotein A1 (mg/dL) | 132 | 18 | 131 | 0.14* |
| Apolipoprotein B (mg/dL) | 73 | 20 | 69 | 0.07 |
| LDL diameter (nm) | 270 | 5 | 269 | 0.02 |
| Fasting glucose (mg/dL) | 89 | 7 | 89 | 0.00 |
| Fasting insulin (μU/mL) | 8.4 | 3.6 | 8.0 | 0.15* |
| HOMA IR | 1.87 | 0.84 | 1.75 | 0.12 |
| HOMA β cell | 6.66 | 3.09 | 6.08 | 0.15* |
| Serum adiponectin (μg/mL) | 6.9 | 2.8 | 6.4 | -0.08 |
| CRP (mg/L) | 0.51 | 1.45 | 0.16 | — |

**P* ≤ .05.

†*P* < .01.

‡*P* < .001 or less.

Abbreviations: BP, blood pressure; bpm, beats per minutes; QTc, heart-rate corrected QT; HOMA IR and β cell, insulin resistance and secretion estimated using homeostasis model assessment, respectively.

Low-density lipoprotein (LDL)-cholesterol was calculated using the formula of Friedwald et al.²⁷ The diameter of the major LDL fraction was determined by gradient gel electrophoresis on 2% to 16% polyacrylamide gels (Biocraft, Tokyo, Japan) according to the method of Nicolset al.²⁸

IR and secretion (β cell) determined by homeostasis model assessment²⁹ (HOMA) were calculated using fasting plasma glucose and insulin levels in each participant. HOMA IR has been validated by comparison with results of glucose clamp studies,^{29,30} intravenous glucose tolerance test,^{29,31} and continuous infusion of glucose with model assessment.³¹ The HOMA β-cell method has been validated by comparison with the intravenous glucose model assessment.³² Application of HOMA has also been used in epidemiological studies.^{29,33,34}

CRP and adiponectin concentrations were measured in sera stored at -70°C using a highly sensitive immunonephelometric assay³⁵ and an enzyme-linked immunosorbent assay (ELISA),³⁶ respectively. The intra-assay and interassay coefficients of variation of adiponectin were 3.3% and 7.4%, respectively, and those of CRP were less than 5%.

Statistical analysis was performed with the SAS statistical software system (SAS Institute, Cary, NC). Spearman's simple regression analysis and stepwise multiple regression analysis with backward elimination procedure were performed to discriminate variables affecting CRP. Because the distribution became normally distributed after log transformation, logarithmically transformed values of CRP (log CRP) were used. *P* values less than .05 were considered significant. Data are expressed as means ± SD unless otherwise stated.

RESULTS

Characteristics of these young men are shown in Table 1. CRP averaged 0.51 ± 1.45 mg/L with a median value of 0.16

mg/L. Spearman's rank correlation coefficients for CRP are also shown in Table 1. Although CRP was positively correlated with BMI, percentage body fat, and serum leptin, the correlation with serum leptin (*r* = 0.28) was stronger than the correlations with BMI (*r* = 0.15) and percent body fat (*r* = 0.16). CRP was also associated with resting heart rate and QTc interval, whereas it showed no association with systolic and diastolic blood pressure. HDL-cholesterol (*r* = -0.26) and apolipoprotein A1 (*r* = -0.14) showed significantly negative relationship with CRP. In contrast, triglyceride (*r* = 0.14) showed a positive correlation, and LDL-cholesterol and apolipoprotein B showed no correlation with CRP. CRP concentrations were related to fasting insulin levels (*r* = 0.15) and HOMA β-cell (*r* = 0.15) but not to HOMA IR or serum adiponectin concentrations.

Stepwise multiple regression analysis (Table 2), which included smoking status, HOMA IR, and all variables that showed significant univariate associations with CRP in Table 1, revealed that leptin, QTc duration, and HDL-cholesterol (inversely) were independently associated with log CRP and explained 15% of CRP variability. However, HOMA IR did not emerge as an independent determinant of CRP.

DISCUSSION

We have shown in the present study that CRP was independently related to serum leptin, QTc interval, and HDL-cholesterol (inversely) in young, apparently healthy men. It should be noted in the present study that the independent association of circulating CRP concentrations was found in a sample of male college students who had few confounding risk factors.

The reasons for the association between CRP and serum leptin, QTc interval, and HDL-cholesterol are not clear and it is clearly not possible, in a cross-sectional study, to attribute causality to one of a set of correlated variables, but several explanations are possible, which are not necessarily exclusive. As previously reported,⁶⁻¹³ and confirmed in the present study, BMI was associated with CRP. In the present study, however, the association of CRP with leptin was stronger than that with BMI or percent body fat. Leptin is an extremely robust circulating marker of the percentage of fat mass. Thus, its correlation with CRP is biologically plausible because both leptin and cytokines, such as interleukin-6 which promotes CRP secretion from the liver, are produced by adipocytes.^{1,2} Increases in serum leptin may be a consequence of low-grade inflammation.³⁷ This may be compatible with the recent observation by Limieux et al³⁸ who used hydrostatic weighing and computed tomography to make state-of-the-art assessments of body fat and found that the amount of total body fat was the best

Table 2. Stepwise Multiple Regression Analysis for Log CRP as the Dependent Variable

| Independent Variable | β | SE (β) | <i>P</i> Values | Partial <i>R</i> ² (%) |
|----------------------|--------|--------|-----------------|-----------------------------------|
| Serum leptin | 0.086 | 0.029 | .003 | 8.9 |
| QTc duration | 0.009 | 0.003 | .014 | 11.8 |
| HDL-cholesterol | -0.022 | 0.008 | .010 | 14.8 |

NOTE. The model includes smoking status, HOMA IR, and all variables that showed significant relation to CRP in Table 1.

correlate of CRP levels in healthy middle-aged men with a wide range of BMI (21 to 41 kg/m²).

QTc interval prolongation has been reported to be common in obesity³⁹ and people with an unfavorable balance between sympathetic and parasympathetic activity.⁴⁰ We have recently shown in young, apparently healthy men that fasting serum insulin concentrations are associated with QTc interval independent of serum leptin, percent body fat, and BMI,⁴¹ suggesting that insulin-induced sympathetic activity is one of factors contributing to QTc prolongation. In the present study, however, QTc intervals were strongly associated with CRP, a sensitive marker of inflammation, independently of serum insulin and leptin concentrations, percent body fat, and BMI. These findings suggest that QTc prolongation commonly found in obesity³⁹ may be a result of sympathetic overactivity associated with low-grade inflammation, because inflammation has been shown to stimulate the central nervous system,⁴² leading to activation of the sympathetic nervous system.

Insulin sensitivity measured by a frequently sampled intravenous glucose tolerance test was independently correlated with CRP in the Insulin Resistance and Atherosclerosis Study,⁴³ which included participants with a broad range of insulin sensitivity and diabetes status. However, in the present study performed in young healthy men, CRP was not associated with insulin sensitivity estimated using HOMA IR, which showed a surprisingly good correlation with insulin sensitivity measured using the hyperinsulinemic euglycemic clamp technique,⁴⁴ the gold standard in the measurement of insulin sensitivity. It is unlikely, therefore, that the discrepancy between the 2 studies is due to the difference in the measurement in insulin sensitivity. The striking difference between the 2 studies is in BMI and CRP levels in addition to their age. BMI averaged 21.8 and 28.4 kg/m² and CRP averaged 0.50 ± 1.45 and 3.53 ± 0.18 mg/L, respectively, in the present study and in the Insulin Resistance Atherosclerosis Study.⁴³ Recently, CRP concentrations have been reported to be associated with total fat mass,³⁸ as described earlier. This association was independent of insulin levels assessed over times during a 75-g oral glucose load (a crude marker of IR in nondiabetic subjects). In addition, there was no association between CRP and adiponectin, an insulin-sensitizing adipocytokine, replenishment of which has been reported to increase insulin sensitivity in different models of IR in vivo.^{45,46} Therefore we believe that low-grade inflammation may be associated primarily with body fat, and then modified by IR, although the fact that the partic-

ipants were all healthy and had a narrow range of CRP and HOMA-IR might make it impossible to associate CRP with abnormalities of IR in the present study.

Associations between CRP levels and lipoprotein profile have been observed in children and adults.^{7,9,12,13,19,21} These associations between CRP and triglyceride and HDL-cholesterol have been reported to persist after adjustment for BMI.^{7,13,19} However, in the report focusing on a detailed analysis of body composition using state-of-the-art assessments of body fat,³⁸ CRP levels were not associated with variables of the lipoprotein-lipid profile in middle-aged men with atherogenic dyslipidemia associated with the metabolic syndrome. We have previously shown that serum HDL-cholesterol concentrations are associated with triglyceride-rich lipoprotein metabolism and body fat in young healthy men.²⁵ Therefore, an inverse and independent association between HDL-cholesterol and CRP found in the present study suggests that low HDL-cholesterol may be related to chronic low-grade inflammation, as well as subtle abnormalities in triglyceride-rich lipoprotein metabolism²⁵ in young healthy men. Low HDL-cholesterol in low-grade inflammation in the present study may be compatible with the recent observation⁴⁷ that human secretory phospholipase A2, an acute-phase protein, decreased HDL-cholesterol in response to inflammation.

Several limitations of this study deserve mention. First, because the study is cross-sectional, the directionality of associations cannot be conclusively established. Second, study results might be a chance or bias and could be explained by possible confounders that were not included. Third, we used a single CRP measurement that may not accurately reflect long-term inflammation status. However, because random misclassification due to biological variability will lead to underestimation of true associations, this limitation is unlikely to explain our findings.

In conclusion, in young, apparently healthy men, we found significant relationships between CRP concentrations and serum leptin, QTc interval, and HDL-cholesterol (inversely). However, there was not a relationship with BMI and other components of IR, possibly due to the healthy status of the participants.

ACKNOWLEDGMENT

We thank Dr Takeo Sadamitsu and Tetsuo Ogawa and Akira Yanoue for their help in preparing the manuscript.

REFERENCES

- Hotamisligil GC, Shargill NS, Spiegelman BM: Adipose expression of tumor necrosis factor- α : Direct role in obesity-linked insulin resistance. *Science* 259:87-91, 1993
- Mohamed-Ali V, Goodrich S, Rawesh A, et al: Subcutaneous adipose tissue releases interleukin-6, but not tumor necrosis factor- α , in vivo. *J Clin Endocrinol Metab* 82:4196-4200, 1997
- Castell JV, Gomez-Lechon MJ, David M, et al: Interleukin-6 is the major regulator of acute phase protein synthesis in adult human hepatocytes. *FEBS Lett* 242:237-239, 1989
- Baumann H, Gaudie J: Regulation of hepatic acute phase plasma protein genes by hepatocyte stimulating factors and other mediators of inflammation. *Mol Biol Med* 7:147-159, 1990
- Heinrich PC, Castell JV, Andus T: Interleukin-6 and the acute phase response. *Biochem J* 265:621-636, 1990
- Kuller LH, Tracy RP, Shaten J, et al: Relation of C-reactive protein and coronary heart disease in the MRFIT nested case-control study. Multiple Risk Factor Intervention Trial. *Am J Epidemiol* 144: 537-547, 1996
- Mendall MA, Patel P, Ballam L, et al: C reactive protein and its relation to cardiovascular risk factors: A population based cross sectional study. *Br Med J* 312:1061-1065, 1996
- Haverkate F, Thompson SG, Pyke SDM, et al: Production of C reactive protein and risk of coronary events in stable and unstable angina. European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group. *Lancet* 349:462-466, 1997

9. Tracy RP, Psaty BM, Macy E, et al: Lifetime smoking exposure affects the association of C-reactive protein with cardiovascular disease risk factors and subclinical disease in healthy elderly subjects. *Arterioscler Thromb Vasc Biol* 17:2167-2176, 1997
10. Ford ES: Body mass index, diabetes, and C-reactive protein among U.S. adults. *Diabetes Care* 22:1971-1977, 1999
11. Visser M, Bouter LM, McQuillan GM, et al: Elevated C reactive protein levels in overweight and obese adults. *JAMA* 282:2131-2135, 1999
12. Yudkin JS, Stehouwer CD, Emeis JJ, et al: C-reactive protein in healthy subjects: Associations with obesity, insulin resistance, and endothelial dysfunction: A potential role for cytokines originating from adipose tissue? *Arterioscler Thromb Vasc Biol* 19:972-978, 1999
13. Hak AE, Stehouwer CD, Bots ML, et al: Associations of C-reactive protein with measures of obesity, insulin resistance, and subclinical atherosclerosis in healthy, middle-aged women. *Arterioscler Thromb Vasc Biol* 19:1986-1991, 1999
14. Tracy RP, Lemaitre RN, Psaty B, et al: Relationship of C-reactive protein to risk of cardiovascular disease in the elderly: Result from the Cardiovascular Health Study and the Rural Health Promotion Project. *Arterioscler Thromb Vasc Biol* 17:1121-1127, 1997
15. Ridker PM, Cushman M, Stampfer MJ, et al: Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. *N Engl J Med* 336:973-979, 1997
16. Koenig W, Frohlich M, Sund M, et al: C-reactive protein (CRP) predicts risk of coronary heart disease (CHD) in healthy middle-aged men: Results from the MONICA-Augsburg cohort study, 1984-1992. *Circulation* 99:237-242, 1999
17. Danesh J, Muir J, Wolg Y-K, et al: Risk factors for coronary heart disease and acute-phase proteins: A population-based study. *Eur Heart J* 20:954-959, 1999
18. Frohlich M, Imhof A, Berg G, et al: Association between C-reactive protein and features of the metabolic syndrome. A population-based study. *Diabetes Care* 23:1835-1839, 2000
19. Cook DG, Mendall MA, Whincup PH, et al: C-reactive protein concentration in children: Relationship to adiposity and other cardiovascular risk factors. *Atherosclerosis* 149:139-150, 2000
20. Danesh J, Whincup P, Lennon L, et al: Low grade inflammation and coronary heart disease: Prospective study and updated meta-analyses. *Br Med J* 321:199-204, 2000
21. Chambers JC, Eda S, Bassett P, et al: C-reactive protein, insulin resistance, central obesity, and coronary heart disease risk in Indian Asians from the United Kingdom compared with European whites. *Circulation* 104:145-150, 1999
22. Friihbeck G, Salvador J: Relation between leptin and glucose metabolism. *Diabetologia* 43:3-12, 2000
23. Berg AH, Combs TP, Schere PE: ACRP30/ adiponectine: An adiponectine regulating glucose and lipid metabolism. *Trends Endocrinol Metab* 13:84-89, 2002
24. Kazumi T, Kawaguchi A, Katoh J, et al: Fasting insulin and leptin serum levels are associated with systolic blood pressure independent of percentage body fat and body mass index. *J Hypertens* 17:1451-1455, 1999
25. Kazumi T, Kawaguchi A, Hozumi T, et al: Serum HDL cholesterol values are associated with apoB-containing lipoprotein metabolism and triglyceride-body fat interrelation in young Japanese men. *Atherosclerosis* 130:93-100, 1997
26. McLaughlin NB, Campbell RW, Murray A: Comparison of automated QT measurement techniques in the normal 12 lead electrocardiogram. *Br Heart J* 74:84-89, 1995
27. Friedwald WT, Levy RI, Fredrickson DS: Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. *Clin Chem* 18:499-502, 1972
28. Nichols AV, Krauss RM, Musliner TA: Nondenaturing polyacrylamide gradients gel electrophoresis, in Segrest JP, Albert JJ, (eds): *Methods in Enzymology*, vol 128, Plasma Lipoproteins, Part A, Preparation, Structure and Molecular Biology. Orlando, FL, Academic Press, 1986, pp 417-431
29. Haffner SM, Miettinen H, Stern MP: The homeostasis model in the San Antonio Heart Study. *Diabetes Care* 20:1087-1092, 1997
30. Emoto M, Nishizawa Y, Maekawa K, et al: Homeostasis model assessment as a clinical index of insulin resistance in type 2 diabetic patients treated with sulfonylureas. *Diabetes Care* 22:818-822, 1999
31. Hermans MP, Levy JC, Morris RJ, et al: Comparison of insulin sensitivity tests across a range of glucose tolerance from normal to diabetes. *Diabetologia* 42:678-687, 1999
32. Hermans MP, Levy JC, Morris RJ, et al: Comparison of tests of β -cell function across a range of glucose tolerance from normal to diabetes. *Diabetologia* 42:1779-1786, 1999
33. United Kingdom Prospective Diabetes Study Group: United Kingdom Prospective Diabetes Study 24. *Ann Intern Med* 128:165-175, 1998
34. Bomora E, Targher G, Alberiche M, et al: Homeostasis model assessment closely mirrors the glucose clamp technique in the assessment of insulin sensitivity. *Diabetes Care* 23:57-63, 2000
35. Ledue TB, Weiner DL, Sipe JP, et al: Analytical evaluation of particle-enhanced immuno-nephrometric assays for C-reactive protein, serum amyloid A and mannose-binding protein in human serum. *Ann Clin Biochem* 35:745-753, 1998
36. Arita Y, Kihara S, Ouchi N, et al: Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. *Biochem Biophys Res Comm* 257:79-83, 1999
37. Loffreda S, Yang SQ, Lia HZ, et al: Leptin regulates proinflammatory immune response. *FASEB J* 12:57-65, 1998
38. Lemieux I, Poirier A, Prud'homme D, et al: Elevated C-reactive protein. Another component of the atherothrombotic profile of abdominal obesity. *Arterioscler Thromb Vasc Biol* 21:961-967, 2001
39. Carella MJ, Mantz SL, Rovner DR, et al: Obesity, adiposity, and lengthening of the QT interval: Improvement after weight loss. *Int J Obesity* 20:938-942, 1996
40. Dekker JM, Schouten EG, Klootwijk P, et al: Association between QT interval and coronary heart disease in middle-aged and elderly men. The Zutphen Study. *Circulation* 90:779-785, 1994
41. Kazumi T, Kawaguchi A, Katoh J, et al: Fasting serum insulin concentrations are associated with QTc interval independent of serum leptin, percent body fat, and BMI. *Diabetes Care* 22:1917-1918, 1999
42. Besedowsky HO, Del Rey A: Immune-neuro-endocrine interactions. *Endocr Rev* 17:664-102, 1996
43. Festa A, D'Agostino R Jr, Howard G, et al: Chronic subclinical inflammation as part of the insulin resistance syndrome. The Insulin Resistance Atherosclerosis Study (IRAS). *Circulation* 102:42-47, 2000
44. Radziuk J: Insulin sensitivity and its measurement: Structural commonalities among the methods. *J Clin Endocrinol Metab* 85:4426-4433, 2000
45. Yamauchi T, Kamon J, Waki H, et al: The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. *Nat Med* 7:941-946, 2001
46. Berg AH, Combs TP, Du X, et al: The adipocyte-secreted protein. Acip 30 enhances hepatic insulin action. *Nat Med* 7:947-953, 2001
47. Tietge UJ, Maugeais C, Land-Katz S, et al: Human secretory phospholipase A2 mediates decreased plasma levels of HDL cholesterol and Apo A-I in response to inflammation in human apo A-I transgenic mice. *Arterioscler Thromb Vasc Biol* 22:1213-1218, 2002